US5153312A
(en)
*
|
1990-09-28 |
1992-10-06 |
American Cyanamid Company |
Oligosaccharide conjugate vaccines
|
US7279162B1
(en)
|
1990-10-22 |
2007-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
|
US5622649A
(en)
*
|
1991-06-27 |
1997-04-22 |
Emory University |
Multiple emulsions and methods of preparation
|
FR2682388B1
(fr)
*
|
1991-10-10 |
1995-06-09 |
Pasteur Merieux Serums Vacc |
Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
|
AU685047B2
(en)
*
|
1992-02-11 |
1998-01-15 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Dual carrier immunogenic construct
|
US7141244B1
(en)
*
|
1992-03-02 |
2006-11-28 |
Chiron Srl |
Helicobacter pylori proteins useful for vaccines and diagnostics
|
US5445817A
(en)
*
|
1992-08-21 |
1995-08-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
|
EP0618813B1
(fr)
*
|
1992-09-16 |
2002-01-09 |
The University Of Tennessee Research Corporation |
Antigene de la proteine m hybride et porteur destine au vaccin anti-streptococcique du groupe a
|
US6531156B1
(en)
|
1994-04-15 |
2003-03-11 |
Temple University |
Aqueous solven encapsulation method, apparatus and microcapsules
|
EP0769019A1
(fr)
*
|
1994-07-01 |
1997-04-23 |
Rican Limited |
Preparation a base de proteine antigene d'helicobacter pylori et dosage immunologique
|
US5565204A
(en)
*
|
1994-08-24 |
1996-10-15 |
American Cyanamid Company |
Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
|
KR19990007777A
(ko)
*
|
1995-06-07 |
1999-01-25 |
듀크두플레시스 |
면역성 및 면역자극성 올리고당 조성물 및 이를 제조하고 이용하는 방법
|
US6284884B1
(en)
|
1995-06-07 |
2001-09-04 |
North American Vaccine, Inc. |
Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
|
US5866132A
(en)
*
|
1995-06-07 |
1999-02-02 |
Alberta Research Council |
Immunogenic oligosaccharide compositions
|
US5695768A
(en)
*
|
1995-06-07 |
1997-12-09 |
Alberta Research Council |
Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
|
ATE433329T1
(de)
|
1995-06-23 |
2009-06-15 |
Glaxosmithkline Biolog Sa |
Impfstoff bestehend aus auf aluminium-phosphat adsorbiertem, konjugiertem polysaccharid antigen
|
US6872398B2
(en)
*
|
1995-12-22 |
2005-03-29 |
The United States Of America As Represented By The Secretary Of The Army |
Conjugate vaccine against gram-negative bacterial infections
|
EP0909323B1
(fr)
|
1996-01-04 |
2007-02-28 |
Novartis Vaccines and Diagnostics, Inc. |
Bacterioferritine de helicobacter pilori
|
ZA97248B
(en)
*
|
1996-01-18 |
1997-07-18 |
Rohm & Haas |
Method for identifying and quantifying polymers utilizing immunoassay techniques
|
US6207157B1
(en)
|
1996-04-23 |
2001-03-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Conjugate vaccine for nontypeable Haemophilus influenzae
|
US6309646B1
(en)
|
1996-05-09 |
2001-10-30 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
|
DE69708318T3
(de)
*
|
1996-08-27 |
2006-11-16 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
|
US6299881B1
(en)
*
|
1997-03-24 |
2001-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
|
US6610293B1
(en)
|
1997-06-16 |
2003-08-26 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
|
US5847110A
(en)
*
|
1997-08-15 |
1998-12-08 |
Biomedical Frontiers, Inc. |
Method of reducing a schiff base
|
JP2001518556A
(ja)
|
1997-10-03 |
2001-10-16 |
ガレニカ ファーマシューティカルズ, インコーポレイテッド |
イミン形成ポリサッカライド、その調製、ならびにアジュバントおよび免疫刺激剤としてのその使用
|
WO1999039739A1
(fr)
|
1998-02-05 |
1999-08-12 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Procede simplifie d'elimination de proteine libre en cours de preparation de conjugues de proteine-polysaccharide et vaccins utilisant un support a acces restreint
|
BR9907884A
(pt)
*
|
1998-02-12 |
2000-10-24 |
American Cyanamid Co |
Composição de vacina, processos para gerar uma resposta imune em um antìgeno pneumocócico, para aumentar resposta de ifn-gama em uma vacina pneumocócica, e para gerar anticorpos de fixação complementar para uma resposta protetora a um patógeno, composição imunogênica, e, processo para gerar uma resposta imune em um antìgeno meningocócico
|
US7018637B2
(en)
*
|
1998-02-23 |
2006-03-28 |
Aventis Pasteur, Inc |
Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
|
EP1073667A2
(fr)
|
1998-04-28 |
2001-02-07 |
Galenica Pharmaceuticals, Inc. |
Conjugues d'antigene et de polysaccharide
|
US7250494B2
(en)
*
|
1998-06-15 |
2007-07-31 |
Biosynexus Incorporated |
Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
|
US6858211B1
(en)
*
|
1998-07-20 |
2005-02-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vaccines against Escherichia coli O157 infection
|
DE69941574D1
(de)
*
|
1998-08-19 |
2009-12-03 |
Baxter Healthcare Sa |
Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
|
US6797275B1
(en)
*
|
1998-12-04 |
2004-09-28 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
|
US6146902A
(en)
*
|
1998-12-29 |
2000-11-14 |
Aventis Pasteur, Inc. |
Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
|
GB9928196D0
(en)
*
|
1999-11-29 |
2000-01-26 |
Chiron Spa |
Combinations of B, C and other antigens
|
FR2806304B1
(fr)
*
|
2000-03-17 |
2002-05-10 |
Aventis Pasteur |
Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
|
US7749511B2
(en)
*
|
2000-04-18 |
2010-07-06 |
Endobiologics, Incorporated |
Anti-sepsis conjugate vaccine
|
JP2004515450A
(ja)
*
|
2000-04-18 |
2004-05-27 |
エンドバイオロジックス, インコーポレイテッド |
敗血症処置のためのリポ多糖結合体ワクチン
|
JP2004506086A
(ja)
*
|
2000-08-25 |
2004-02-26 |
アベンティス、パストゥール、リミテッド |
インフルエンザ菌感染症の予防用ワクチンとしてのインフルエンザ菌リポ多糖内部コアオリゴ糖エピトープ
|
US7723296B2
(en)
|
2001-01-18 |
2010-05-25 |
Genzyme Corporation |
Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
|
PL226184B1
(pl)
|
2001-01-23 |
2017-06-30 |
Aventis Pasteur |
Poliwalentna sprzezona szczepionka meningokokowa polisacharyd- bialko
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
WO2003018054A1
(fr)
*
|
2001-08-31 |
2003-03-06 |
Chiron Srl. |
Vaccination contre helicobacter pylori avec une combinaison de proteines caga, vaca et nap
|
GB0129007D0
(en)
*
|
2001-12-04 |
2002-01-23 |
Chiron Spa |
Adjuvanted antigenic meningococcal compositions
|
WO2003070909A2
(fr)
|
2002-02-20 |
2003-08-28 |
Chiron Corporation |
Microparticules comprenant des molecules adsorbees qui contiennent polypeptides
|
EP1476197B1
(fr)
*
|
2002-02-22 |
2009-01-07 |
National Research Council Of Canada |
Synthese de vaccins conjugues de proteine-lipopolysaccharide au moyen de la region lipidique apres retrait du residu de phosphate glycosidique
|
AU2002309259A1
(en)
*
|
2002-05-09 |
2003-11-11 |
Massimo Porro |
Improved polysaccharide and glycoconjugate vaccines_____________
|
DE60328481D1
(de)
|
2002-05-14 |
2009-09-03 |
Novartis Vaccines & Diagnostic |
Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
|
GB0211118D0
(en)
*
|
2002-05-15 |
2002-06-26 |
Polonelli Luciano |
Vaccines
|
PT2255826E
(pt)
|
2002-08-02 |
2016-06-08 |
Glaxosmithkline Biologicals Sa |
Composições de vacina de neisseria compreendendo uma combinação de antigénios
|
SI1549338T1
(sl)
|
2002-10-11 |
2011-04-29 |
Novartis Vaccines & Diagnostic |
Polipeptidna cepiva za ĺ iroko zaĺ äśito pred hipervirulentnimi miningokoknimi rodovi
|
AU2003278166B2
(en)
|
2002-11-01 |
2009-01-29 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004060396A2
(fr)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenes contenant des compositions de phospholipide
|
FR2850106B1
(fr)
|
2003-01-17 |
2005-02-25 |
Aventis Pasteur |
Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
|
CA2514328C
(fr)
|
2003-01-30 |
2020-01-14 |
Chiron Srl |
Vaccins injectables contre les multiples serogroupes du meningocoque
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
EP2386313A1
(fr)
|
2003-05-07 |
2011-11-16 |
Sanofi Pasteur, Inc. |
Conjugués de polysaccharides-protéines dérivatisés méningococciques multivalents et vaccin
|
WO2005004909A2
(fr)
|
2003-05-07 |
2005-01-20 |
Aventis Pasteur, Inc. |
Methode permettant d'obtenir une immunogenicite amelioree par rapport a la vaccination meningococcique
|
WO2005020964A1
(fr)
|
2003-06-02 |
2005-03-10 |
Chiron Corporation |
Compositions immunogenes basees sur des microparticules comprenant des antigenes contenant de l'anatoxine adsorbee et des polysaccharides
|
GB0313916D0
(en)
|
2003-06-16 |
2003-07-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
EP2851088A1
(fr)
*
|
2003-06-23 |
2015-03-25 |
Baxter International Inc. |
Vaccins contre la Neisseria Y meningoccal mengingitidis et leurs combinaisons
|
MXPA05014171A
(es)
|
2003-06-23 |
2007-02-21 |
Sanofi Pasteur Inc |
Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c.
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
EP1961426B1
(fr)
|
2003-10-02 |
2011-04-27 |
Novartis Vaccines and Diagnostics S.r.l. |
Vaccins combinés contre la méningite
|
US8574596B2
(en)
|
2003-10-02 |
2013-11-05 |
Glaxosmithkline Biologicals, S.A. |
Pertussis antigens and use thereof in vaccination
|
UA93854C2
(ru)
|
2003-12-17 |
2011-03-25 |
Вайет Ллк |
Иммуногенный конъюгат и способ его получения
|
MY144231A
(en)
|
2003-12-17 |
2011-08-15 |
Wyeth Corp |
Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
|
US7422755B2
(en)
*
|
2004-01-15 |
2008-09-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Antimultiorganism glycoconjugate vaccine
|
US20050169941A1
(en)
*
|
2004-01-29 |
2005-08-04 |
Andrew Lees |
Use of amino-oxy functional groups in the preparation of protein-polysaccharide conjugate vaccines
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
GB0408978D0
(en)
|
2004-04-22 |
2004-05-26 |
Chiron Srl |
Meningococcal fermentation for preparing conjugate vaccines
|
SI1740217T1
(sl)
|
2004-04-30 |
2011-10-28 |
Novartis Ag |
Konjugirano meningokokno cepljenje
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
EP1768662A2
(fr)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
|
EP2277595A3
(fr)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Composés pour potentialiser l'immunité
|
EP2612679A1
(fr)
|
2004-07-29 |
2013-07-10 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions immunogènes pour une bactérie à gram positif telle que streptococcus agalactiae
|
KR20070101207A
(ko)
|
2004-08-30 |
2007-10-16 |
사노피 파스퇴르 인크 |
다가 수막구균 유도체화된 다당류-단백질 접합체 및 백신
|
GB0420466D0
(en)
*
|
2004-09-14 |
2004-10-20 |
Cassone Antonio |
Anti-glucan antibodies
|
MX2007003292A
(es)
|
2004-09-21 |
2007-09-07 |
Sanofi Pasteur Inc |
Conjugados y vacuna con proteinas de polisacarido derivadas meningococales multivalentes.
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0502096D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Purification of streptococcal capsular polysaccharide
|
GB0505518D0
(en)
|
2005-03-17 |
2005-04-27 |
Chiron Srl |
Combination vaccines with whole cell pertussis antigen
|
GB0505996D0
(en)
|
2005-03-23 |
2005-04-27 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
AU2011253684B8
(en)
*
|
2005-04-08 |
2013-07-11 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
US7709001B2
(en)
*
|
2005-04-08 |
2010-05-04 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
CN113198012A
(zh)
*
|
2005-04-08 |
2021-08-03 |
惠氏有限责任公司 |
多价肺炎球菌多糖-蛋白质缀合物组合物
|
US7955605B2
(en)
|
2005-04-08 |
2011-06-07 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
US20070184072A1
(en)
|
2005-04-08 |
2007-08-09 |
Wyeth |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
CN103083657B
(zh)
|
2005-06-27 |
2016-06-08 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合物
|
EP1931380A2
(fr)
|
2005-09-01 |
2008-06-18 |
Novartis Vaccines and Diagnostics GmbH & Co. KG |
Vaccination multiple comprenant des meningocoques du serogroupe c
|
JP5044754B2
(ja)
*
|
2005-09-21 |
2012-10-10 |
アメリカ合衆国 |
カンピロバクター・ジェジュニに対するワクチン成分として使用される免疫原莢膜組成物
|
US9999591B2
(en)
*
|
2005-09-21 |
2018-06-19 |
The United States Of America As Represented By The Secretary Of The Navy |
Immunogenic composition against Campylobacter jejuni
|
US7700578B2
(en)
*
|
2005-09-21 |
2010-04-20 |
The United States Of America As Represented By The Secretary Of The Navy |
Capsule composition for use as immunogen against Campylobacter jejuni
|
GB0522303D0
(en)
|
2005-11-01 |
2005-12-07 |
Chiron Srl |
Culture method
|
ES2514316T3
(es)
|
2005-11-22 |
2014-10-28 |
Novartis Vaccines And Diagnostics, Inc. |
Partículas similares a virus (VLPs) de Norovirus y Sapovirus
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AR058707A1
(es)
|
2005-12-22 |
2008-02-20 |
Glaxosmithkline Biolog Sa |
Vacuna, procedimiento para fabricarla y su uso
|
JP4822854B2
(ja)
*
|
2006-01-18 |
2011-11-24 |
株式会社有沢製作所 |
フレキシブルプリント配線板用ポリアミドイミド樹脂、並びに該樹脂を用いた金属張り積層板、カバーレイ、フレキシブルプリント配線板、及び樹脂組成物
|
GB0605757D0
(en)
|
2006-03-22 |
2006-05-03 |
Chiron Srl |
Separation of conjugated and unconjugated components
|
TR201807355T4
(tr)
|
2006-03-22 |
2018-06-21 |
Glaxosmithkline Biologicals Sa |
Meningokokkal konjugatlarla immünizasyon rejimleri.
|
CA2647100A1
(fr)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Procedes de preparation de composes contenant de l'imidazole
|
WO2007109812A2
(fr)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Composes de potentialisation immunitaire
|
ES2536426T3
(es)
|
2006-03-23 |
2015-05-25 |
Novartis Ag |
Compuestos de imidazoquinoxalina como inmunomoduladores
|
US8808707B1
(en)
|
2006-05-08 |
2014-08-19 |
Wyeth Llc |
Pneumococcal dosing regimen
|
EP2035035A2
(fr)
|
2006-06-09 |
2009-03-18 |
Novartis AG |
Compositions immunogenes pour streptococcus agalactiae
|
ES2658851T3
(es)
|
2006-08-07 |
2018-03-12 |
President And Fellows Of Harvard College |
Vacunas de matriz de proteína y métodos de preparación y administración de tales vacunas
|
CN101553246B
(zh)
*
|
2006-08-07 |
2019-05-21 |
哈佛大学校长及研究员协会 |
蛋白质基质疫苗及这种疫苗的制备和给药方法
|
NZ575273A
(en)
|
2006-09-07 |
2012-02-24 |
Glaxosmithkline Biolog Sa |
Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid
|
GB0700136D0
(en)
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
CN101631794B
(zh)
*
|
2007-01-18 |
2013-01-02 |
建新公司 |
包含氨基氧基基团的寡糖及其轭合物
|
US20100074918A1
(en)
|
2007-05-02 |
2010-03-25 |
Jan Poolman |
Vaccine
|
NZ581367A
(en)
|
2007-06-04 |
2012-05-25 |
Novartis Ag |
Formulation of meningitis vaccines containing haemophilus influenzae and neisseria meningitidis
|
EP2167121B1
(fr)
|
2007-06-26 |
2015-09-02 |
GlaxoSmithKline Biologicals S.A. |
Vaccin contenant des conjugues de polysaccharide capsulaire de streptococcus pneumoniae
|
RU2471497C2
(ru)
|
2007-09-12 |
2013-01-10 |
Новартис Аг |
Мутантные антигены gas57 и антитела против gas57
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
CN101977926B
(zh)
|
2007-12-21 |
2014-10-08 |
诺华股份有限公司 |
链球菌溶血素o的突变形式
|
HUE029265T2
(en)
|
2008-10-27 |
2017-02-28 |
Glaxosmithkline Biologicals Sa |
Method of purifying carbohydrates from the group streptococci
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
LT2889043T
(lt)
|
2008-12-16 |
2019-07-10 |
Genzyme Corporation |
Sintetiniai tarpiniai junginiai oligosacharido-baltymo konjugatų gamybai
|
WO2010079464A1
(fr)
|
2009-01-12 |
2010-07-15 |
Novartis Ag |
Antigènes à domaines cna_b dans des vaccins contre des bactéries à gram positif
|
US9050283B2
(en)
|
2009-01-16 |
2015-06-09 |
University Of Maryland, Baltimore |
Broad spectrum vaccine against non-typhoidal Salmonella
|
US20120135037A1
(en)
|
2009-06-01 |
2012-05-31 |
Mizel Steven B |
Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
|
US8647621B2
(en)
|
2009-07-27 |
2014-02-11 |
Fina Biosolutions, Llc |
Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
|
BR112012009014B8
(pt)
|
2009-09-30 |
2022-10-04 |
Novartis Ag |
Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
|
GB0917647D0
(en)
|
2009-10-08 |
2009-11-25 |
Glaxosmithkline Biolog Sa |
Expression system
|
EP3199177A1
(fr)
|
2009-10-30 |
2017-08-02 |
GlaxoSmithKline Biologicals S.A. |
Purification de saccharides capsulaires de staphylococcus aureus de type 5 et de type 8
|
MX2012006961A
(es)
|
2009-12-17 |
2012-10-03 |
Fina Biosolutions Llc |
Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas.
|
JP5781542B2
(ja)
|
2009-12-30 |
2015-09-24 |
ノバルティス アーゲー |
E.coliキャリアタンパク質に結合体化した多糖免疫原
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
JP2013521326A
(ja)
|
2010-03-10 |
2013-06-10 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
JP2013522287A
(ja)
|
2010-03-18 |
2013-06-13 |
ノバルティス アーゲー |
血清群b髄膜炎菌のためのアジュバント添加ワクチン
|
JP2013529894A
(ja)
|
2010-04-07 |
2013-07-25 |
ノバルティス アーゲー |
パルボウイルスb19のウイルス様粒子を生成するための方法
|
US20130116423A1
(en)
|
2010-04-23 |
2013-05-09 |
A. Stewart Campbell |
Synthetic Oligosaccharides for Staphylococcus Vaccine
|
NZ602971A
(en)
|
2010-04-23 |
2014-11-28 |
Serum Inst India Ltd |
Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
|
US8716469B2
(en)
|
2010-04-27 |
2014-05-06 |
Ancora Pharmaceuticals, Inc. |
Synthetic oligosaccharides for Moraxella vaccine
|
WO2011149778A1
(fr)
|
2010-05-26 |
2011-12-01 |
Ancora Pharmaceuticals Inc. |
Oligosaccharides synthétiques pour un vaccin contre neisseria meningitidis
|
WO2012006293A1
(fr)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Compositions immunogènes dérivées d'un norovirus et méthodes
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
EP2655389A2
(fr)
|
2010-12-24 |
2013-10-30 |
Novartis AG |
Composés
|
CN102068690A
(zh)
*
|
2010-12-31 |
2011-05-25 |
北京民海生物科技有限公司 |
多价肺炎球菌荚膜多糖结合疫苗及其制备方法
|
CN103533954B
(zh)
|
2011-03-02 |
2015-09-09 |
诺华股份有限公司 |
含较低剂量的抗原和/或佐剂的联合疫苗
|
EP2691431B1
(fr)
|
2011-03-29 |
2017-06-21 |
Covestro Deutschland AG |
Utilisation d'une préparation aqueuse pour revêtement de surfaces en bois destinée à créer une sensation de toucher naturel
|
WO2012130764A1
(fr)
|
2011-03-29 |
2012-10-04 |
Bayer Materialscience Ag |
Utilisation d'une préparation aqueuse pour revêtement de surfaces en bois destinée à créer une sensation de toucher naturel
|
GB201106225D0
(en)
|
2011-04-13 |
2011-05-25 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
CN103764171B
(zh)
|
2011-07-08 |
2016-08-17 |
诺华股份有限公司 |
酪氨酸连接方法
|
US10030052B2
(en)
|
2011-07-25 |
2018-07-24 |
Glaxosmithkline Biologicals Sa |
Parvovirus Vp1 unique region polypeptides and compositions thereof
|
EP2755683B1
(fr)
|
2011-09-14 |
2019-04-03 |
GlaxoSmithKline Biologicals SA |
Procédés de production de glycoconjugués de saccharide-protéine
|
WO2013068949A1
(fr)
|
2011-11-07 |
2013-05-16 |
Novartis Ag |
Molécule porteuse comprenant un antigène spr0096 et un antigène spr2021
|
DE102011118371B4
(de)
|
2011-11-11 |
2014-02-13 |
Novartis Ag |
Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
|
EP2592137A1
(fr)
|
2011-11-11 |
2013-05-15 |
Novartis AG |
Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
|
GB2495341B
(en)
|
2011-11-11 |
2013-09-18 |
Novartis Ag |
Fermentation methods and their products
|
DE102011122891B4
(de)
|
2011-11-11 |
2014-12-24 |
Novartis Ag |
Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
JP2015509963A
(ja)
|
2012-03-08 |
2015-04-02 |
ノバルティス アーゲー |
Tlr4アゴニストを含む混合ワクチン
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
MX2014014067A
(es)
|
2012-05-22 |
2015-02-04 |
Novartis Ag |
Conjugado de serogrupo x de meningococo.
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
CA2882619A1
(fr)
|
2012-09-06 |
2014-03-13 |
Novartis Ag |
Vaccins combinatoires avec meningococcus de serogroupe b et d/t/p
|
ES2672996T3
(es)
|
2012-10-02 |
2018-06-19 |
Glaxosmithkline Biologicals Sa |
Conjugados de sacáridos no lineales
|
SG10201702685WA
(en)
|
2012-10-03 |
2017-04-27 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
MX2015004652A
(es)
|
2012-10-12 |
2015-08-05 |
Glaxosmithkline Biolog Sa |
Antigenos de pertusis acelulares no entrelazados para uso en vacunas de combinacion.
|
KR20140075196A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
EP2743695A1
(fr)
|
2012-12-12 |
2014-06-18 |
Nanogap Sub NM Powder, S.A. |
Procédés et réactifs pour la détection de biomolécules au moyen de luminescence
|
JP2016502994A
(ja)
|
2012-12-18 |
2016-02-01 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ジフテリア及び/又は破傷風から防御するためのコンジュゲート
|
SI3363806T1
(sl)
*
|
2012-12-20 |
2023-04-28 |
Pfizer Inc. |
Postopek glikokonjugacije
|
ITMI20130142A1
(it)
*
|
2013-01-31 |
2014-08-01 |
Biosynth Srl |
Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
|
BR112015021523A8
(pt)
|
2013-03-08 |
2021-06-29 |
Crucell Holland Bv |
composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
|
KR102250099B1
(ko)
*
|
2013-07-07 |
2021-05-10 |
막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. |
스트렙토코커스 뉴모니에 1형에 대한 합성 백신
|
JP6739333B2
(ja)
|
2013-07-11 |
2020-08-12 |
ノバルティス アーゲー |
部位特異的化学酵素的タンパク質修飾
|
CA2923129C
(fr)
|
2013-09-08 |
2020-06-09 |
Pfizer Inc. |
Compositions utilisables contre neisseria meningitidis et procedes associes
|
MX2020001138A
(es)
*
|
2014-01-21 |
2021-09-30 |
Pfizer |
Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
|
US9988426B2
(en)
|
2014-09-18 |
2018-06-05 |
University Of Maryland, Baltimore |
Broad spectrum conjugate vaccine to prevent Klebsiella pneumoniae and Pseudomonas aeruginosa infections
|
US9815886B2
(en)
|
2014-10-28 |
2017-11-14 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
JP2017537145A
(ja)
|
2014-11-05 |
2017-12-14 |
ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーThe United States Of America As Represented By The Secretary Of The Navy |
カンピロバクター・ジェジュニに対する合成抗原コンストラクト
|
US10500261B2
(en)
|
2014-11-05 |
2019-12-10 |
The United States Of America As Represented By The Secretary Of The Navy |
Synthetic antigen constructs against campylobacter jejuni
|
EP3034516A1
(fr)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Purification de polysaccharides capsulaires de streptocoques
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP3377098A1
(fr)
*
|
2015-11-20 |
2018-09-26 |
Pfizer Inc |
Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
EP3269385A1
(fr)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Composition de conjugués de polysaccharide-protéine pneumococcique
|
EP3474890A1
(fr)
|
2016-06-22 |
2019-05-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. |
Composition de conjugué polysaccharide pneumococcique-protéine
|
KR102388325B1
(ko)
|
2016-10-20 |
2022-04-18 |
케이엠 바이올로직스 가부시키가이샤 |
저분자화 PRP를 사용한 Hib 컨쥬게이트 백신의 제조방법
|
EP3551668A1
(fr)
|
2016-12-06 |
2019-10-16 |
GlaxoSmithKline Biologicals S.A. |
Procédé de purification pour polysaccharide capsulaire
|
PE20191107A1
(es)
|
2017-01-31 |
2019-08-26 |
Pfizer |
Composiciones de neisseria meningitidis y metodos respectivos
|
KR20190108583A
(ko)
|
2017-01-31 |
2019-09-24 |
머크 샤프 앤드 돔 코포레이션 |
다당류-단백질 접합체 제조 방법
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
AU2019215216A1
(en)
|
2018-02-05 |
2020-07-23 |
Sk Bioscience Co., Ltd. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
CN111989114A
(zh)
*
|
2018-04-18 |
2020-11-24 |
Sk生物科学株式会社 |
肺炎链球菌的荚膜多糖以及其免疫原性缀合物
|
CN112673054A
(zh)
|
2018-07-19 |
2021-04-16 |
葛兰素史密丝克莱恩生物有限公司 |
用于制备干燥多糖的方法
|
WO2020043874A1
(fr)
|
2018-08-31 |
2020-03-05 |
Glaxosmithkline Biologicals Sa |
Vaccin conjugué contre haemophilus influenzae utilisant une vésicule de membrane externe de bordetella
|
US20220054632A1
(en)
|
2018-12-12 |
2022-02-24 |
Glaxosmithkline Biologicals Sa |
Modified carrier proteins for o-linked glycosylation
|
EP3923982A1
(fr)
|
2019-02-11 |
2021-12-22 |
Pfizer Inc. |
Compositions de neisseria meningitidiset procédés associées
|
EP3757217A1
(fr)
|
2019-06-27 |
2020-12-30 |
GlaxoSmithKline Biologicals S.A. |
Procédés de purification de protéines
|
EP3777884A1
(fr)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Composition immunogène
|
MX2022003682A
(es)
|
2019-09-27 |
2022-04-25 |
Pfizer |
Composiciones de neisseria meningitidis y metodos de las mismas.
|
EP3799884A1
(fr)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Compositions immunogènes
|
EP3900739A1
(fr)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Conjugués saccharides synthétiques de streptococcus pneumoniae à une protéine de membrane conservée
|
EP3919076A1
(fr)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Vaccins synthétiques d'oligosaccharide contre le streptococcus pneumoniae avec des formulations d'adjuvant de microparticules
|
EP4164681A1
(fr)
|
2020-06-12 |
2023-04-19 |
GlaxoSmithKline Biologicals S.A. |
Immunisation bactérienne à l'aide d'un vaccin à nanoparticules
|
US20230226175A1
(en)
|
2020-06-25 |
2023-07-20 |
Glaxosmithkline Biologicals Sa |
Modified exotoxin a proteins
|
JP2023548935A
(ja)
|
2020-11-13 |
2023-11-21 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
新規担体及びコンジュゲーション法
|
WO2023111826A1
(fr)
|
2021-12-14 |
2023-06-22 |
Glaxosmithkline Biologicals Sa |
Immunisation bactérienne utilisant des constructions de nanoparticules en épingle à cheveux qbêta
|
WO2023200704A1
(fr)
|
2022-04-11 |
2023-10-19 |
Sanofi Pasteur Inc. |
Conjugaison protéine-saccharide avec du cyanoborohydrure de sodium
|
GB202215414D0
(en)
|
2022-10-18 |
2022-11-30 |
Glaxosmithkline Biologicals Sa |
Vaccine
|